Agilent Technologies Inc. (NYSE:A) and Signature Genomic Laboratories
LLC (Signature) today announced they have signed a long-term supply
agreement in which Agilent will supply custom oligonucleotide
microarrays to Signature and its customers based on the
Signature-designed SignatureChip Oligo Solution (SignatureChipOS). Terms
of the agreement were not disclosed.
The SignatureChipOS is designed for the detection of chromosome
abnormalities in individuals with mental retardation/developmental
delay, autism and congenital anomalies. The 105,000-feature, 60-mer
microarray covers more than 150 syndromes, the subtelomeric and
pericentromeric regions, and more than 500 genes in important
developmental pathways.
“We’re very pleased
about this agreement, which is the latest example of how the marketplace
is recognizing the value of our highly flexible, high-quality custom
oligonucleotide microarray production capability,”
said Yvonne Linney, Ph.D., Agilent vice president and general manager,
Genomics. “We’re
delighted to work with Signature Genomic Laboratories, which specializes
in microarray technology and is an innovative leader in microarray
testing.”
“We are committed to giving our customers the
best services and technology available, and this agreement reflects this
focus,” said Lisa G. Shaffer, Ph.D., president
and CEO of Signature. “Oligo arrays have
improved dramatically in the past few years, and we are delighted there
are now oligos that meet our high standards. This supply agreement also
allows our Genoglyphix customers the opportunity to use high-quality
oligo arrays for research applications in their laboratories.”
About Signature Genomic Laboratories
Genoglyphix is the innovative software created and used by Signature
Genomic Laboratories. Information about Genoglyphix is available at www.genoglyphix.com.
The SignatureChipOS was developed and its performance characteristics
determined by Signature Genomic Laboratories as required by CLIA ‘88
regulations. It has not been cleared or approved for specific uses by
the U.S. Food and Drug Administration. Pursuant to the requirements of
CLIA ‘88, Signature Genomic Laboratories has
established and verified the test’s accuracy
and precision.
Signature Genomic Laboratories, founded in 2003, was the first
laboratory to provide microarray-based cytogenetic diagnostics with its
proprietary SignatureChip and is the leader in providing
microarray-based chromosome analysis. Signature’s
worldwide client base includes clinical geneticists, neurologists,
pediatricians, neonatologists, obstetricians, and the research
community. Signature is CAP accredited, CLIA certified, and has clinical
licenses from California, Rhode Island and Florida. Additional
information about Signature Genomic Laboratories is available at www.signaturegenomics.com.
About Agilent in Genomics
Agilent is a leading provider of research microarrays used to analyze
gene expression, microRNA, comparative genomic hybridization and
ChIP-on-chip. More information about Agilent microarrays is available at www.opengenomics.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A) is the world’s
premier measurement company and a technology leader in communications,
electronics, life sciences and chemical analysis. The company’s
19,000 employees serve customers in more than 110 countries. Agilent had
net revenue of $5.4 billion in fiscal year 2007. Information about
Agilent is available on the Web at www.agilent.com.
NOTE TO EDITORS: Press releases, photography and other information can
be accessed on the Agilent Life Sciences and Chemical Analysis newsroom
at www.agilent.com/about/newsroom/lsca.
Further technology, corporate citizenship and executive news is
available on the Agilent news site at www.agilent.com/go/news.
